SB Capital Management Inc Buys New Stake in Oramed Pharmaceuticals Inc. $ORMP

SB Capital Management Inc purchased a new position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,900,000 shares of the biotechnology company’s stock, valued at approximately $5,415,000. Oramed Pharmaceuticals makes up 2.0% of SB Capital Management Inc’s investment portfolio, making the stock its 18th largest holding. SB Capital Management Inc owned approximately 4.77% of Oramed Pharmaceuticals at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Marshall Wace LLP bought a new stake in shares of Oramed Pharmaceuticals in the 4th quarter valued at approximately $738,000. BML Capital Management LLC raised its holdings in shares of Oramed Pharmaceuticals by 2.7% in the 3rd quarter. BML Capital Management LLC now owns 3,167,231 shares of the biotechnology company’s stock worth $8,361,000 after buying an additional 83,978 shares in the last quarter. HRT Financial LP bought a new position in shares of Oramed Pharmaceuticals during the 4th quarter worth approximately $131,000. Quadrature Capital Ltd bought a new position in shares of Oramed Pharmaceuticals during the 4th quarter worth approximately $119,000. Finally, Squarepoint Ops LLC boosted its stake in Oramed Pharmaceuticals by 95.1% in the 4th quarter. Squarepoint Ops LLC now owns 58,272 shares of the biotechnology company’s stock valued at $166,000 after buying an additional 28,406 shares in the last quarter. Institutional investors own 12.73% of the company’s stock.

Oramed Pharmaceuticals Stock Performance

Shares of ORMP stock opened at $3.88 on Friday. Oramed Pharmaceuticals Inc. has a 52 week low of $1.98 and a 52 week high of $5.01. The stock has a market capitalization of $158.81 million, a PE ratio of 1.50 and a beta of 1.26. The stock’s fifty day moving average is $3.95 and its 200-day moving average is $3.51.

Oramed Pharmaceuticals (NASDAQ:ORMP) last released its quarterly earnings results on Friday, March 27th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. As a group, analysts forecast that Oramed Pharmaceuticals Inc. will post 0.71 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Oramed Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, June 11th. One analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, Oramed Pharmaceuticals currently has an average rating of “Hold”.

Oramed Pharmaceuticals Profile

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.